Company Overview - Proactive is a publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team operates from key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Market Focus - The company specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive delivers news and insights across various sectors including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for being a forward-looking and enthusiastic adopter of technology, utilizing decades of expertise and experience among its content creators [4] - The company employs automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Company Overview - Medicus Pharma Ltd. is a biotechnology company focused on developing novel therapeutics, particularly in the field of oncology [6][7] - The company's lead asset, SkinJect Inc., is developing a treatment for non-melanoma skin cancer using a patented dissolvable doxorubicin-containing microneedle array (D-MNA) [2][6] Clinical Trials - Medicus is conducting a Phase 2 clinical study (SKNJCT-003) across nine clinical sites in the United States, which began randomizing patients in August 2024 [3] - An interim analysis in March 2025 showed over 60% clinical clearance after more than 50% of the targeted 60 patients were randomized [3] - The investigational review board increased the number of participants in SKNJCT-003 to 90 subjects and expanded clinical trial sites to Europe [3] - A separate clinical study (SKNJCT-004) is underway in the UAE, aiming to randomize 36 patients across four sites [4] Acquisition Plans - In April 2025, Medicus entered into a binding letter of intent to acquire Antev Ltd., a UK-based biotech company developing Teverelix for advanced prostate cancer patients [5][8] - The acquisition is subject to due diligence, negotiation of definitive agreements, and regulatory approvals [8] Upcoming Events - Dr. Raza Bokhari, Executive Chairman and CEO of Medicus, will present corporate updates at the 2025 Bio International Convention on June 17, 2025 [1][2]

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Core Viewpoint - Medicus Pharma Ltd. has submitted a comprehensive product development plan to the FDA to treat external squamous cell carcinoma (SCC) in horses using a novel Doxorubicin-containing microneedle array (D-MNA) patch, aiming for orphan drug designation and a potential market opportunity of $250 million in veterinary oncology [1][5]. Company Developments - The company received a Minor Use in Major Species Designation (MUMS) for its D-MNA in December 2024, which allows for an extended 7-year exclusive marketing period post-approval [2][3]. - The D-MNA is a patented dissolvable transdermal patch designed to deliver Doxorubicin directly to tumors, providing a non-invasive treatment option for equine SCC [4]. Market Opportunity - The veterinary oncology market for treating equine SCC is estimated to be around $250 million, highlighting a significant unmet need in a field with limited approved oncology drugs [5]. Clinical Study Details - The clinical study SKNJCT-004 will enroll up to 50 horses with external SCC, comparing two dose levels of D-MNA against a placebo over a six-month period [9]. - The study will assess the primary effectiveness variable based on a veterinarian's assessment of complete clinical response at day 90 [9]. Previous Clinical Trials - The company previously completed a Phase 1 safety and tolerability study (SKNJCT-001) in humans, which demonstrated good tolerability and efficacy, with 6 out of 13 participants showing complete responses [11]. - A Phase 2 clinical study (SKNJCT-003) is currently underway in the U.S. and has shown promising interim results with over 60% clinical clearance [12]. Expansion Plans - The company is also expanding its clinical trials to Europe and has initiated a study in the UAE, indicating a broader geographical reach for its clinical programs [13][12]. Acquisition Plans - Medicus Pharma has entered into a binding letter of intent to acquire Antev Ltd., a UK-based biotech company, which is developing a next-generation GnRH antagonist for advanced prostate cancer [14][18].

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced news journalists who produce independent content across various financial markets [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered by the team includes insights into sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all published content is edited and authored by humans [5]

Core Viewpoint - Medicus Pharma Ltd. has successfully closed a public offering of 2,260,000 units at a price of $3.10 per unit, which includes common shares and warrants for future purchases [1][2]. Group 1: Offering Details - The offering was conducted on a "best-efforts" basis, with each unit comprising one common share and one warrant to purchase an additional common share at the same price of $3.10, expiring in five years [1][2]. - Maxim Group LLC served as the lead placement agent, with Brookline Capital Markets and D. Boral Capital acting as co-placement agents [2]. Group 2: Use of Proceeds - The net proceeds from the offering will primarily fund a Phase 2 proof of concept clinical trial for treating basal cell carcinoma using a doxorubicin-loaded dissolvable microarray needle skin patch [3]. - Additional proceeds may be allocated to expand the exploratory Phase 2 clinical trial to a pivotal trial and to cover other non-melanoma skin diseases, with any remaining funds directed towards general corporate purposes and working capital [3]. Group 3: Company Overview - Medicus Pharma Ltd. is a biotech/life sciences company focused on advancing clinical development programs for innovative therapeutics [6]. - SkinJect Inc., a wholly owned subsidiary, is developing a non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch [7]. - The company has completed a Phase 1 safety and tolerability study and is currently conducting multiple Phase 2 clinical studies in the United States, Europe, and the UAE [7]. Group 4: Acquisition Plans - In April 2025, the company announced a binding letter of intent to acquire Antev Ltd., a UK-based biotech company developing a next-generation GnRH antagonist for high-risk prostate cancer patients [8]. - The acquisition is subject to due diligence, negotiation of definitive agreements, and obtaining necessary approvals, with no guarantees of successful completion [8].

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Company Overview - Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development of novel therapeutics assets [6] - SkinJect Inc., a wholly owned subsidiary, is developing a non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch [7] Public Offering Details - The company announced a public offering of 2,260,000 units at a price of $3.10 per unit, with each unit consisting of one common share and one warrant [1] - The offering is expected to close on June 2, 2025, subject to customary closing conditions [2] Use of Proceeds - Net proceeds from the offering will fund a Phase 2 proof of concept clinical trial for basal cell carcinoma treatment using a doxorubicin-loaded microarray needle skin patch [3] - Proceeds may also be used to expand exploratory Phase 2 clinical trials to pivotal trials and cover other non-melanoma skin diseases, with remaining funds allocated for general corporate purposes and working capital [3] Acquisition Plans - The company announced a binding letter of intent to acquire Antev Ltd., a UK-based biotech company developing Teverelix for high-risk prostate cancer patients [8] - The acquisition is subject to due diligence, negotiation of definitive agreements, and obtaining necessary approvals [8]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced news journalists who produce independent content across various financial markets [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content includes insights into sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is committed to adopting technology to enhance its content creation and workflow processes [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all published content is edited and authored by humans [5]

Core Insights - Medicus Pharma Ltd. has received approval from the UAE Department of Health to commence a Phase 2 clinical study (SKNJCT-004) for the non-invasive treatment of Basal Cell Carcinoma (BCC) of the skin [1][2] - The study will involve 36 participants across four clinical sites in the UAE, including Cleveland Clinic Abu Dhabi [2][3] - The clinical trial is designed as a randomized, double-blind, placebo-controlled study to evaluate the efficacy of two dose levels of D-MNA compared to a placebo [3][4] Clinical Study Details - The SKNJCT-004 study will randomize participants into three groups: a placebo group, a low-dose group receiving 100μg of D-MNA, and a high-dose group receiving 200μg of D-MNA [3] - The high-dose of 200μg D-MNA is the maximum dose used in the previous Phase 1 study (SKNJCT-001), which met its primary objective of safety and tolerability [4][5] - In the Phase 1 study, D-MNA was well tolerated with no serious adverse events, and six participants achieved complete responses [5] Ongoing and Future Studies - The company is also conducting the SKNJCT-003 Phase 2 clinical study in the United States, which began randomizing patients in August 2024 and has shown a positive interim analysis with over 60% clinical clearance [6][7] - The number of participants in the SKNJCT-003 study has been increased to 90, and the company is expanding clinical trial sites in Europe [7] Strategic Developments - Medicus Pharma has entered into a binding letter of intent to acquire Antev Ltd., a UK-based biotech company developing a next-generation GnRH antagonist for prostate cancer patients [8][11] - The acquisition is subject to due diligence and regulatory approvals, with no guarantees on the completion of the transaction [11] Company Overview - Medicus Pharma Ltd. is focused on accelerating the clinical development of novel therapeutics and has a subsidiary, SkinJect Inc., dedicated to non-invasive treatments for basal cell skin cancer [9][10]